Niflumic acid

Full Generic Medicine Info
Dosage/Direction for Use

Pain and inflammation associated with musculoskeletal and joint disorders
Adult: 250 mg 3 or 4 times daily. Max: 1500 mg daily.

Pain and inflammation associated with musculoskeletal and joint disorders
Adult: 3% cream or ointment or 2.5% gel to be applied to affected areas.
Should be taken with food. Take w/ or immediately after meals.
Active peptic ulceration, severe heart failure.
Special Precautions
Discontinue if hypersensitivity skin reactions occur. Pregnancy, lactation. Elderly, patients with haemorrhagic disorders; hypertension; impaired renal, hepatic, cardiac function; asthma; infections; left ventricular failure; oedema; history of CHF.
Adverse Reactions
CNS disturbances, hypersensitivity reactions, renal/hepatic disorders, GI disturbances, cutaneous reactions, agranulocytosis, neutropenia. Fluid retention, photosensitivity, alveolitis, pulmonary eosinophilia, pancreatitis, Stevens-Johnson syndrome, exacerbation of colitis.
Drug Interactions
May increase concentration of methotrexate, cardiac glycosides. Increased risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus, diuretics. Increased risk of GI bleeding with corticosteroids, SSRIs, venlafaxine, clopidogrel, ticlopidine, iloprost, erlotinib, sibutramine, alcohol, bisphosphonates, pentoxifylline.
Potentially Fatal: May reduce lithium excretion leading to lithium toxicity. May increase effects of anticoagulants.
Niflumic acid is an NSAID derived from nicotinic acid.
CIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M02AA17 - niflumic acid ; Belongs to the class of non-steroidal antiinflammatory preparations for topical use. Used in the treatment of joint and muscular pains.
M01AX02 - niflumic acid ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.
Disclaimer: This information is independently developed by CIMS based on niflumic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in